Replication Attempt: “Effect of BMAP-28 Antimicrobial Peptides on Leishmania Major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival”
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
The three-model screen
all 1,000 screened works →All three models called this metaresearch. It is in the settled core of the field.
A direct replication submitted to the Reproducibility Initiative to independently validate a published result; framed as reproducibility work, though its immediate object is a specific biological claim.
This reports an attempted replication and independent validation of prior experiments, making reproducibility the object of study.
Independent replication attempt submitted to the Reproducibility Initiative; primary object is whether prior results replicate.
Abstract
This study describes an attempt to replicate experiments from the paper "Effect of BMAP-28 Antimicrobial Peptides on Leishmania major Promastigote and Amastigote Growth: Role of Leishmanolysin in Parasite Survival," which was submitted to the Reproducibility Initiative for independent validation. The cathelicidin bovine myeloid antimicrobial peptide 28 (BMAP-28) and its isomers were previously shown to have potent antiparasitic activity against Leishmania major. We tested the effectiveness of L-BMAP-28 and two of its isomers, the D-amino acid form (D-BMAP-28) and the retro-inverso form (RI-BMAP-28), in both unamidated and amidated forms, as anti-leishmanial agents against Leishmania major promastigotes in vitro. We observed that L-BMAP-28, as well as its D and RI isomers, demonstrate anti-leishmanial activity against L. major promastigotes in vitro. The inhibitory effect was lower than what was seen in the original study. At 2 µM of amidated peptides, the viability was 94%, 36%, and 66% with L-, D- and RI-peptides, versus 57%, 6%, and 18% in the original study.
Stored with the screening record, where it is evidence for the labels above.
The record
- Venue
- PLoS ONE
- Topic
- Research on Leishmaniasis Studies
- Field
- Medicine
- Canadian institutions
- —
- Funders
- University of California, San DiegoMcMaster UniversityBroad InstituteWashington University in St. LouisStanford Bio-XUniversity of MiamiOregon Health and Science University
- Keywords
- AmastigoteLeishmaniaAntimicrobialBiologyMicrobiologyLeishmania majorAntimicrobial peptidesPeptideAntiparasiticCathelicidinIn vitroAntiparasitic agentParasite hostingPharmacologyBiochemistryMedicine
- Has abstract in OpenAlex
- yes